← back to search

Alexis Laurent

Université de Caen Normandie · FR
Area of research
Hepatology · Surgery
Research interest
Research interests include Hepatocellular Carcinoma Treatment and Prognosis, Cholangiocarcinoma and Gallbladder Cancer Studies, Organ Transplantation Techniques and Outcomes, and Liver Disease Diagnosis and Treatment.
h-index
74
citations
25,899
works
397
NIH funding
primary concept
Medicine
email

Recent publications

Minimally Invasive Spleen‐Preserving Distal Pancreatectomy in Obese Patients: Factors Related to Clinically Relevant Pancreatic Fistula
International Journal of Medical Robotics and Computer Assisted Surgery 2025cited by 4position: middledoi
Laparoscopic liver resection in high-risk anesthesia patients A French nationwide study.
2025cited by 0position: contributordoi
Combined hepatocellular-cholangiocarcinoma compared to hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Different survival, similar recurrence: Report of a large study on repurposed databases with propensity score matching.
2024cited by 14position: contributordoi
Conversion to open surgery in obese patients undergoing minimally invasive distal pancreatectomy: results from a multicenter analysis
HPB 2024cited by 7position: middledoi
Risk factors for emergency surgery for diverticulitis: A retrospective multicentric French study at 41 hospitals
Surgery 2024cited by 1position: contributordoi
Should Hypervascular Incidentalomas Detected on Per-Interventional Cone Beam Computed Tomography during Intra-Arterial Therapies for Hepatocellular Carcinoma Impact the Treatment Plan in Patients Waiting for Liver Transplantation?
2024cited by 0position: contributordoi
Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma
Nature Communications 2023cited by 74position: middledoi
Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
2023cited by 59position: contributordoi
Robotic versus laparoscopic distal pancreatectomy in obese patients
Surgical Endoscopy 2023cited by 16position: middledoi
Paradigm shift: should preoperative 3D reconstruction models become mandatory before hepatectomy for hepatocellular carcinoma (HCC)? Results of a multicenter prospective trial.
2023cited by 7position: contributordoi
Data from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 6 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 7 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 3 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Data from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Data from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 1 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 5 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Data from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 2 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 4 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 4 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 2 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 5 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 7 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 6 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 1 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 3 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 8 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi
Supplementary Table 8 from Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 30 papers (2020–2025)Jessica Zucman‐Rossi · Inserm29 papers (2013–2023)Stefano Caruso · Université Paris-Est Créteil25 papers (2019–2023) · 24 papers (2019–2023) · 24 papers (2020–2024)Luca Di Tommaso · Hôpitaux Universitaires Henri-Mondor23 papers (2020–2023) · 21 papers (2022–2023)Jérémy Augustin · Centre de Recherche Saint-Antoine21 papers (2022–2023)David Gentien · Université Paris Sciences et Lettres21 papers (2022–2023)Loetitia Favre · Texas Neurofibromatosis Foundation21 papers (2022–2023)Hong Son Trinh · Hôpitaux Universitaires Henri-Mondor21 papers (2022–2023)Anaïs Pujals · Texas Neurofibromatosis Foundation21 papers (2022–2023)Fouad Lafdil · Hôpitaux Universitaires Henri-Mondor21 papers (2022–2023) · 21 papers (2022–2023)Thi Lan Tran · Bạch Mai Hospital21 papers (2022–2023)Van Ky Le · Hôpitaux Universitaires Henri-Mondor21 papers (2022–2023)Nicola De’angelis · Community Healthlink9 papers (2020–2022)Luca Aldrighetti · Erasmus MC Cancer Institute6 papers (2020–2022)Francesca Ratti · Vita-Salute San Raffaele University6 papers (2020–2022)Julien Caldéraro · Inserm6 papers (2013–2020)